Maxim Rossmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maxim Rossmann has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- David Robert Spring
Yusuf Hamied Department of Chemistry University of Cambridge Cambridge UK
8 shared publications - Marko Hyvönen
University of Cambridge
6 shared publications - Ashok R. Venkitaraman
National University of Singapore 19 Singapore
4 shared publications Grahame J. McKenzie
The Medical Research Council Cancer Unit, University of Cambridge, Hills Road, Cambridge, CB2 0XZ, United Kingdom
4 shared publicationsJamie E. Stokes
Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, United Kingdom
3 shared publicationsMarko Hyvönen
Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Old Addenbrooke’s Site, Cambridge CB2 1GA
3 shared publications
Latest Publications
- Open Access
Selective Aurora A-TPX2 interaction inhibitors have in vivo efficacy as targeted anti-mitotic agents
The protein kinase Aurora A, and its close relative, Aurora B, regulate human cell division. Aurora A is frequently overexpressed in cancers of the breast, ovary, pancreas and blood, provoking genome instability and resistance to anti-mitotic chemotherapy. Intracellular localization and enzymatic activity of Aurora A are regulated by its interaction with the spindle assembly factor TPX2. Here, we have used fragment-based, structure-guided lead discovery to develop small-molecule inhibitors of the Aurora A-TPX2 protein-protein interaction (PPI). These compounds act by novel mechanism compared to existing Aurora A inhibitors and they are highly specific to Aurora A over Aurora B. Our biophysically, structurally and phenotypically validated lead compound, CAM2602 , exhibits oral bioavailability, favourable pharmacokinetics, pharmacodynamic biomarker modulation, and arrest of growth in tumour xenografts. Consistent with our original finding that Aurora A overexpression drives taxane-resistance in cancer cells, inhibition of Aurora A-TPX2 PPI synergizes with paclitaxel to suppress the outgrowth of pancreatic cancer cells. Our results provide a blueprint for targeting the Aurora A-TPX2 PPI for cancer therapy and suggest a promising clinical utility for this mode of action.
Open AccessSelective Aurora A-TPX2 interaction inhibitors have in vivo efficacy as targeted anti-mitotic agents
The protein kinase Aurora A, and its close relative, Aurora B, regulate human cell division. Aurora A is frequently overexpressed in cancers of the breast, ovary, pancreas and blood, provoking genome instability and resistance to anti-mitotic chemotherapy. Intracellular localization and enzymatic activity of Aurora A are regulated by its interaction with the spindle assembly factor TPX2. Here, we have used fragment-based, structure-guided lead discovery to develop small-molecule inhibitors of the Aurora A-TPX2 protein-protein interaction (PPI). These compounds act by novel mechanism compared to existing Aurora A inhibitors and they are highly specific to Aurora A over Aurora B. Our biophysically, structurally and phenotypically validated lead compound, CAM2602 , exhibits oral bioavailability, favourable pharmacokinetics, pharmacodynamic biomarker modulation, and arrest of growth in tumour xenografts. Consistent with our original finding that Aurora A overexpression drives taxane-resistance in cancer cells, inhibition of Aurora A-TPX2 PPI synergizes with paclitaxel to suppress the outgrowth of pancreatic cancer cells. Our results provide a blueprint for targeting the Aurora A-TPX2 PPI for cancer therapy and suggest a promising clinical utility for this mode of action.
- Open Access
- 22 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Publisher Correction: Somatic genetic rescue of a germline ribosome assembly defect
- 22 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Open AccessPublisher Correction: Somatic genetic rescue of a germline ribosome assembly defect
- Open Access
- 4 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 15930
A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation
The human polo-like kinase PLK1 coordinates mitotic chromosome segregation by phosphorylating multiple chromatin- and kinetochore-binding proteins. How PLK1 activity is directed to specific substrates via phosphopeptide recognition by its carboxyl-terminal polo-box domain (PBD) is poorly understood. Here, we combine molecular, structural and chemical biology to identify a determinant for PLK1 substrate recognition that is essential for proper chromosome segregation. We show that mutations ablating an evolutionarily conserved, Tyr-lined pocket in human PLK1 PBD trigger cellular anomalies in mitotic progression and timing. Tyr pocket mutations selectively impair PLK1 binding to the kinetochore phosphoprotein substrate PBIP1, but not to the centrosomal substrate NEDD1. Through a structure-guided approach, we develop a small-molecule inhibitor, Polotyrin, which occupies the Tyr pocket. Polotyrin recapitulates the mitotic defects caused by mutations in the Tyr pocket, further evidencing its essential function, and exemplifying a new approach for selective PLK1 inhibition. Thus, our findings support a model wherein substrate discrimination via the Tyr pocket in the human PLK1 PBD regulates mitotic chromosome segregation to preserve genome integrity.
- 4 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 15930
Open AccessA cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation
The human polo-like kinase PLK1 coordinates mitotic chromosome segregation by phosphorylating multiple chromatin- and kinetochore-binding proteins. How PLK1 activity is directed to specific substrates via phosphopeptide recognition by its carboxyl-terminal polo-box domain (PBD) is poorly understood. Here, we combine molecular, structural and chemical biology to identify a determinant for PLK1 substrate recognition that is essential for proper chromosome segregation. We show that mutations ablating an evolutionarily conserved, Tyr-lined pocket in human PLK1 PBD trigger cellular anomalies in mitotic progression and timing. Tyr pocket mutations selectively impair PLK1 binding to the kinetochore phosphoprotein substrate PBIP1, but not to the centrosomal substrate NEDD1. Through a structure-guided approach, we develop a small-molecule inhibitor, Polotyrin, which occupies the Tyr pocket. Polotyrin recapitulates the mitotic defects caused by mutations in the Tyr pocket, further evidencing its essential function, and exemplifying a new approach for selective PLK1 inhibition. Thus, our findings support a model wherein substrate discrimination via the Tyr pocket in the human PLK1 PBD regulates mitotic chromosome segregation to preserve genome integrity.
- Open Access
- 20 February 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (11) , 3041-3049
Second-generation CK2α inhibitors targeting the αD pocket
CK2 is a critical cell cycle regulator that also promotes various anti-apoptotic mechanisms. Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases. We have previously utilised a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066. Whilst CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site. This second generation αD-site binding inhibitor, compound CAM4712 (IC50 = 7 μM, GI50 = 10.0 ± 3.6 μM), has numerous advantages over the previously reported CAM4066, including a reduction in the number of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability. Unlike with CAM4066, there was no need to facilitate cellular uptake by making a prodrug. Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC50) and the ability to inhibit cell proliferation (GI50).
- 20 February 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (11) , 3041-3049
Open AccessSecond-generation CK2α inhibitors targeting the αD pocket
CK2 is a critical cell cycle regulator that also promotes various anti-apoptotic mechanisms. Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases. We have previously utilised a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066. Whilst CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site. This second generation αD-site binding inhibitor, compound CAM4712 (IC50 = 7 μM, GI50 = 10.0 ± 3.6 μM), has numerous advantages over the previously reported CAM4066, including a reduction in the number of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability. Unlike with CAM4066, there was no need to facilitate cellular uptake by making a prodrug. Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC50) and the ability to inhibit cell proliferation (GI50).
- Open Access
- 2 August 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (67) , 9372-9375
Computationally-guided optimization of small-molecule inhibitors of the Aurora A kinase–TPX2 protein–protein interaction
Computational binding free energy predictions were validated against experiment and used to design new inhibitors of an important protein–protein interaction.
- 2 August 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (67) , 9372-9375
Open AccessComputationally-guided optimization of small-molecule inhibitors of the Aurora A kinase–TPX2 protein–protein interaction
Computational binding free energy predictions were validated against experiment and used to design new inhibitors of an important protein–protein interaction.
- Open Access
- 24 April 2017
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 30 (6) , 419-430
Development of a multipurpose scaffold for the display of peptide loops
Protein–protein interactions (PPIs) determine a wide range of biological processes and analysis of these dynamic networks is increasingly becoming a mandatory tool for studying protein function. Using the globular ATPase domain of recombinase RadA as a scaffold, we have developed a peptide display system (RAD display), which allows for the presentation of target peptides, protein domains or full-length proteins and their rapid recombinant production in bacteria. The design of the RAD display system includes differently tagged versions of the scaffold, which allows for flexibility in the protein purification method, and chemical coupling for small molecule labeling or surface immobilization. When combined with the significant thermal stability of the RadA protein, these features create a versatile multipurpose scaffold system. Using various orthogonal biophysical techniques, we show that peptides displayed on the scaffold bind to their natural targets in a fashion similar to linear parent peptides. We use the examples of CK2β/CK2α kinase and TPX2/Aurora A kinase protein complexes to demonstrate that the peptide displayed by the RAD scaffold can be used in PPI studies with the same binding efficacy but at lower costs compared with their linear synthetic counterparts.
- 24 April 2017
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 30 (6) , 419-430
Open AccessDevelopment of a multipurpose scaffold for the display of peptide loops
Protein–protein interactions (PPIs) determine a wide range of biological processes and analysis of these dynamic networks is increasingly becoming a mandatory tool for studying protein function. Using the globular ATPase domain of recombinase RadA as a scaffold, we have developed a peptide display system (RAD display), which allows for the presentation of target peptides, protein domains or full-length proteins and their rapid recombinant production in bacteria. The design of the RAD display system includes differently tagged versions of the scaffold, which allows for flexibility in the protein purification method, and chemical coupling for small molecule labeling or surface immobilization. When combined with the significant thermal stability of the RadA protein, these features create a versatile multipurpose scaffold system. Using various orthogonal biophysical techniques, we show that peptides displayed on the scaffold bind to their natural targets in a fashion similar to linear parent peptides. We use the examples of CK2β/CK2α kinase and TPX2/Aurora A kinase protein complexes to demonstrate that the peptide displayed by the RAD scaffold can be used in PPI studies with the same binding efficacy but at lower costs compared with their linear synthetic counterparts.
- 15 July 2016
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 353 (6296) , 295-299
Structural basis for integration of GluD receptors within synaptic organizer complexes
Transmitting signals across the synapse: Glutamate receptors located on neuronal cells play a role in mediating electrical signals at excitatory synapses. These glutamatergic synapses are extremely important for nearly all cognitive functions. Elegheert et al. analyzed a complex that bridges the synapse, comprising β-neurexin 1, a cell adhesion molecule on the surface of presynaptic axons; cerebellin 1, a synaptic organizer; and the postsynaptic glutamate receptor GluD2. The structural and functional analysis provides insight into the mechanism of synaptic signaling. Science , this issue p. 295
- 15 July 2016
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 353 (6296) , 295-299
Structural basis for integration of GluD receptors within synaptic organizer complexes
Transmitting signals across the synapse: Glutamate receptors located on neuronal cells play a role in mediating electrical signals at excitatory synapses. These glutamatergic synapses are extremely important for nearly all cognitive functions. Elegheert et al. analyzed a complex that bridges the synapse, comprising β-neurexin 1, a cell adhesion molecule on the surface of presynaptic axons; cerebellin 1, a synaptic organizer; and the postsynaptic glutamate receptor GluD2. The structural and functional analysis provides insight into the mechanism of synaptic signaling. Science , this issue p. 295
- Open Access
- 24 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 28528
Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2
The essential mitotic kinase Aurora A (AURKA) is controlled during cell cycle progression via two distinct mechanisms. Following activation loop autophosphorylation early in mitosis when it localizes to centrosomes, AURKA is allosterically activated on the mitotic spindle via binding to the microtubule-associated protein, TPX2. Here, we report the discovery of AurkinA, a novel chemical inhibitor of the AURKA-TPX2 interaction, which acts via an unexpected structural mechanism to inhibit AURKA activity and mitotic localization. In crystal structures, AurkinA binds to a hydrophobic pocket (the ‘Y pocket’) that normally accommodates a conserved Tyr-Ser-Tyr motif from TPX2, blocking the AURKA-TPX2 interaction. AurkinA binding to the Y- pocket induces structural changes in AURKA that inhibit catalytic activity in vitro and in cells, without affecting ATP binding to the active site, defining a novel mechanism of allosteric inhibition. Consistent with this mechanism, cells exposed to AurkinA mislocalise AURKA from mitotic spindle microtubules. Thus, our findings provide fresh insight into the catalytic mechanism of AURKA and identify a key structural feature as the target for a new class of dual-mode AURKA inhibitors, with implications for the chemical biology and selective therapeutic targeting of structurally related kinases.
- 24 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 28528
Open AccessAllosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2
The essential mitotic kinase Aurora A (AURKA) is controlled during cell cycle progression via two distinct mechanisms. Following activation loop autophosphorylation early in mitosis when it localizes to centrosomes, AURKA is allosterically activated on the mitotic spindle via binding to the microtubule-associated protein, TPX2. Here, we report the discovery of AurkinA, a novel chemical inhibitor of the AURKA-TPX2 interaction, which acts via an unexpected structural mechanism to inhibit AURKA activity and mitotic localization. In crystal structures, AurkinA binds to a hydrophobic pocket (the ‘Y pocket’) that normally accommodates a conserved Tyr-Ser-Tyr motif from TPX2, blocking the AURKA-TPX2 interaction. AurkinA binding to the Y- pocket induces structural changes in AURKA that inhibit catalytic activity in vitro and in cells, without affecting ATP binding to the active site, defining a novel mechanism of allosteric inhibition. Consistent with this mechanism, cells exposed to AurkinA mislocalise AURKA from mitotic spindle microtubules. Thus, our findings provide fresh insight into the catalytic mechanism of AURKA and identify a key structural feature as the target for a new class of dual-mode AURKA inhibitors, with implications for the chemical biology and selective therapeutic targeting of structurally related kinases.
- Open Access
- 26 February 2016
- Published by Wiley in ChemBioChem
- Vol. 17 (8) , 689-692
Development of a Multifunctional Benzophenone Linker for Peptide Stapling and Photoaffinity Labelling
Photoaffinity labelling is a useful method for studying how proteins interact with ligands and biomolecules, and can help identify and characterise new targets for the development of new therapeutics. We present the design and synthesis of a novel multifunctional benzophenone linker that serves as both a photo‐crosslinking motif and a peptide stapling reagent. Using double‐click stapling, we attached the benzophenone to the peptide via the staple linker, rather than by modifying the peptide sequence with a photo‐crosslinking amino acid. When applied to a p53‐derived peptide, the resulting photoreactive stapled peptide was able to preferentially crosslink with MDM2 in the presence of competing protein. This multifunctional linker also features an extra alkyne handle for downstream applications such as pull‐down assays, and can be used to investigate the target selectivity of stapled peptides.
- 26 February 2016
- Published by Wiley in ChemBioChem
- Vol. 17 (8) , 689-692
Open AccessDevelopment of a Multifunctional Benzophenone Linker for Peptide Stapling and Photoaffinity Labelling
Photoaffinity labelling is a useful method for studying how proteins interact with ligands and biomolecules, and can help identify and characterise new targets for the development of new therapeutics. We present the design and synthesis of a novel multifunctional benzophenone linker that serves as both a photo‐crosslinking motif and a peptide stapling reagent. Using double‐click stapling, we attached the benzophenone to the peptide via the staple linker, rather than by modifying the peptide sequence with a photo‐crosslinking amino acid. When applied to a p53‐derived peptide, the resulting photoreactive stapled peptide was able to preferentially crosslink with MDM2 in the presence of competing protein. This multifunctional linker also features an extra alkyne handle for downstream applications such as pull‐down assays, and can be used to investigate the target selectivity of stapled peptides.
- Open Access
- 1 January 2016
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Molecular Science
- Vol. 3 (4) , 635-647
Intracellular calcium excess as one of the main factors in the etiology of prostate cancer
Numerous studies show that prostate cancer (PCa) incidence drastically increases with age, these malignant tumours are mainly formed in the peripheral zone of the prostate gland, and a high intake of calcium rich dairy products is associated with an increased risk of PCa. The main objective of this study was to identify a potential common pathophysiological factor associated with the PCa features mentioned above. We performed measurements of the intracellular Ca concentrations in the peripheral zones of nonhyperplastic prostate glands of 99 males aged 0–87 years. To clarify the age-related changes in the intracellular Ca, a quantitative morphometric and two analytical methods of Ca determination were employed. We found, that in 18–45 years old males intracellular Ca was maintained at a relatively high concentration, which steadily increased with age. The intracellular Ca accumulation increased after the age of 45. We found, that by the age of 55, Ca level in the prostatic cells of the peripheral zone reached concentration, which is two-to-four-fold higher than in the 18 year olds. Age-dependent accumulation of Ca in the peripheral zone of human prostate gland has been previously unrecognized and could play an important role in the etiology of PCa
- 1 January 2016
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Molecular Science
- Vol. 3 (4) , 635-647
Open AccessIntracellular calcium excess as one of the main factors in the etiology of prostate cancer
Numerous studies show that prostate cancer (PCa) incidence drastically increases with age, these malignant tumours are mainly formed in the peripheral zone of the prostate gland, and a high intake of calcium rich dairy products is associated with an increased risk of PCa. The main objective of this study was to identify a potential common pathophysiological factor associated with the PCa features mentioned above. We performed measurements of the intracellular Ca concentrations in the peripheral zones of nonhyperplastic prostate glands of 99 males aged 0–87 years. To clarify the age-related changes in the intracellular Ca, a quantitative morphometric and two analytical methods of Ca determination were employed. We found, that in 18–45 years old males intracellular Ca was maintained at a relatively high concentration, which steadily increased with age. The intracellular Ca accumulation increased after the age of 45. We found, that by the age of 55, Ca level in the prostatic cells of the peripheral zone reached concentration, which is two-to-four-fold higher than in the 18 year olds. Age-dependent accumulation of Ca in the peripheral zone of human prostate gland has been previously unrecognized and could play an important role in the etiology of PCa